Pfizer’s US deal gives Novartis and Roche wings on the stock exchange
Keystone-SDA
Pharmaceutical stocks rebounded in a big way on the Zurich stock exchange in the wake of a tariff agreement reached by Pfizer in the United States.
+Get the most important news from Switzerland in your inbox
Long under pressure due to intentions to regulate drug prices in the US, companies are breathing a sigh of relief after US giant Pfizer was granted a three-year immunity against any prohibitive surcharges wielded by President Donald Trump in exchange for a series of concessions.
+ How pharma became Switzerland’s Achilles heel in the US
Considering that this new business model could become the new normal, analysts welcome the decrease in uncertainty for the entire industry. Investors welcome the developments taking place and the effect on the stock exchange was not lacking: at midday on Wednesday Roche gained 5.3%, Novartis 2.4% and Lonza 0.8%.
Pfizer’s preparations will be sold more cheaply under the government’s Medicaid health programme, Trump indicated at a press conference last night. The president also announced the creation of the ‘TrumpRx’ website, which will offer patients direct access to drugs at discounted prices in order to “bypass the middlemen”.
+ How will US tariffs affect the pharma industry?
US investments
In addition to the price reductions, Pfizer has promised to invest over $70 billion in research, development and domestic production.
Trump’s plans include bringing medicine prices in the US in line with lower prices in other rich countries. In the summer, he had asked 17 major pharmaceutical companies, including Novartis and Roche, to reduce their prices according to this principle. It had set a deadline by the end of September and threatened high tariffs.
+ The high stakes fight over drug prices
Pfizer is only the first company with which a deal has been reached, Trump pointed out. “We’ll make deals with everybody, I’m on the waiting list,” he said. And if there is no deal, then there will be tariffs, he added.
The Swiss pharmaceutical giants would not let on whether they are currently negotiating similar packages. “We have been in discussions with the government on how to meet the demands,” Novartis indicated to the Awp news agency.
“We remain committed to finding constructive solutions that reduce costs for Americans and address price differences between the US and other high-income countries.”
Roche’s reaction was similar. “We continue to work closely with the US government to achieve our common goals of strengthening US manufacturing and improving the affordability of medicines for patients in the United States,” the company notes. At the same time, the group reports on its plans to invest $50 billion in the US over the next five years.
More
More
How drug prices are negotiated in Switzerland and beyond
Translated from Italian by DeepL/mga
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch.
